Profile: Agenus Inc (AGEN.O)
23 Jun 2017
Agenus Inc. (Agenus), incorporated on November 10, 1999, is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of CPM antibodies.
The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, AutoSynVax vaccine (ASV) and PhosphoSynVax vaccine (PSV). Its synthetic (ASV and PSV) vaccine candidates are protein complexes that consist of HSPs and peptides that are either tumor-derived or tailor-made based on the genomic fingerprint of a patient's tumor, respectively. Its Prophage cancer vaccine candidate, HSPPC-96, is an autologous cancer vaccine therapy derived from cancer tissues that are surgically removed from an individual patient. QS-21 Stimulon is an adjuvant, which is a substance added to a vaccine or other immunotherapy that is intended to enhance an immune response to the target antigens.
The Company competes with Bristol-Myers Squibb, Merck, Ono Pharmaceuticals, AstraZeneca, Pfizer, Novartis, Roche, Tesaro, Beigene, Regeneron, CureTech, Eli Lilly, Jiangsu HengRui Medicine, Shanghai Junshi, Macrogenics, Regeneron, Advaxis, Janssen, Eisai, Arbor Pharmaceuticals, Green Cross Cell, ImmunoCellular Therapeutics, Northwest Biotherapeutics, Mimivax Inc., Annias Immunotherapeutics, Activartis Biotech, TVAX Biomedical, Stemline Therapeutics, Sumitomo Dainippon Pharma, Idera, Colby, Dynavax, Valneva, GlaxoSmithKline plc, Adjuvance Technologies, Inc., CSL Limited, Novavax, Inc., Neon Therapeutics, Gritstone Oncology, BioNTech, Moderna, Nouscom, Immatics and Green Peptides.
3 Forbes Rd
LEXINGTON MA 02421-7305
Company Web Links
- BRIEF-AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY
- BRIEF-Agenus Q1 loss per share $0.18
- BRIEF-Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins
- BRIEF-Agenus commences phase 1 trial with neoantigen cancer vaccine autosynvax
- BRIEF-Agenus says plans to close Basel site, combine key functions to Cambridge, UK and Lexington, MA facilities